Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Wendys Co (WEN) vs GeneDx Holdings Corp (WGS) Price & Performance

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Wendys Co vs GeneDx Holdings Corp — how do they compare? Wendys Co trades at $6.23 (market cap $1.19B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Wendys Co pays a 4.49% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wendys Co for 77 Days and GeneDx Holdings Corp for 19 Days on average.

WENWGS
Market Cap
$1.19B$2.02B
Volume
5,622,905734,640
Sector
Consumer CyclicalHealth
52-Week High
$9.33$167.51
52-Week Low
$6.10$34.51
Typical Hold Time
77 Days19 Days
Enterprise Value
$4.92B$2.05B
Dividend Yield
4.49%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Wendys Co

Wendy's stock trades at $6.23, up 1.96% today, but remains under significant pressure with a bearish technical outlook. The company faces declining same-store sales, a major franchisee bankruptcy, and net income margin compression from 7.58% in 2025 to 5.72% projected for 2026. Despite beating earnings expectations in recent quarters, valuation metrics appear attractive with P/E of 9.45 and P/S of 0.54, though high debt levels and competitive pressures persist.

The investment case hinges on new CEO Bob Wright's turnaround execution against substantial headwinds. While the stock trades at a discount to analyst consensus target of $7.58, near-term risks from franchisee instability and market share losses to burger chain competitors outweigh valuation appeal. Recovery depends on reversing sales trends and managing $2.66 billion in long-term debt effectively.

GeneDx Holdings Corp

GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.

While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

WEN
100% Buy0% Sell
Avg holding period · 77 Days
WGS
100% Buy0% Sell
Avg holding period · 19 Days

About Wendys Co

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.

Read more on WEN →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →